The PPARγ Pro12Ala variant is associated with insulin sensitivity in Russian normoglycaemic and type 2 diabetic subjects

Diabetes and Vascular Disease Research

Volumn 7, Issue 1, 2010, Pages 56-62

  Chistiakov, Dimitry A ^a   Potapov, Viktor A ^a   Khodirev, Dmitry S ^a   Shamkhalova, Minara S ^a   Shestakova, Marina V ^b   Nosikov, Valery V ^a  

^a STATE RESEARCH INSTITUTE OF GENETICS AND SELECTION OF INDUSTRIAL MICROORGANISMS   (Russian Federation)

^b N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

Author keywords

Insulin resistance; Insulin sensitivity; Peroxisome proliferator activated receptor ; PPARG Pro12Ala gene variant; Susceptibility; Type 2 diabetes

Indexed keywords

ALANINE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PROLINE; TRIACYLGLYCEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOCYTE; ADIPOGENESIS; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DETERMINATION; FEMALE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INSULIN METABOLISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID STORAGE; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; RUSSIAN FEDERATION; BLOOD; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; RISK FACTOR;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HOMOZYGOTE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; PPAR GAMMA; RISK FACTORS; RUSSIA;

EID: 77949416113     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.1177/1479164109347689     Document Type: Article

References (37)

1. Cecil JE, Watt P, Palmer CN, Hetherington M. (2006) Energy balance and food intake: the role of PPARγ gene polymorphisms. Physiol Behav 88: 227-233.
2. Meirhaeghe A, Amouyel P. (2004) Impact of genetic variation of PPARγ in humans. Mol Genet Metab 83: 93-102.
3. Rosen ED, Hsu CH, Wang X, et al. (2002) C/EBPa induces adipogenesis through PPARγ: a unified pathway. Genes Dev 16: 22-26.
4. Yen CY, Beamer BA, Negri C. (1997) Molecular scanning of the human peroxisome proliferator activated receptor γ (hPPARγ) gene in diabetic Caucasians: identification of a Pro12Ala PPARγ2 missense mutation. Biochem Biophys Res Commun 241: 270-274.
5. Deeb SS, Fajas L, Nemoto M, et al. (1998) A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20: 284-287.
6. Masugi J, Tamori Y, Mori H, Koike T, Kasuga M. (2000) Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator activated receptor-γ2 on thiazolidinedione- induced adipogenesis. Biochem Biophys Res Commun 268: 178-182.
7. Altshuler D, Hirschhorn JN, Klannemark M, et al. (2000) The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26: 76-80.
8. Mori H, Ikegami H, Kawaguchi Y, et al. (2001) The Pro12Ala substitution in PPAR-γ is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 50: 891-894.
9. Lindi VI, Uusitupa MI, Lindstrom J, et al. (2002) Association of the Pro12Ala polymorphism in the PPAR-γ2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes 51: 2581-2586.
10. Scott LJ, Mohlke KL, Bonnycastle LL, et al. (2007) A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316: 1341-1345.
11. Tonjes A, Stumvoll M. (2007) The role of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor γ in diabetes risk. Curr Opin Clin Nutr Metab Care 10: 410-414.
12. Stumvoll M, Haring H. (2002) The peroxisome proliferator- activated receptor-γ2 Pro12Ala polymorphism. Diabetes 51: 2341-2347.
13. Khemlani SL. Prevention of type 2 diabetes is crucial. Available at
14. Alberti KGMM, Zimmet PZ. (1998) WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation. Diabet Med 15: 539-553.
15. Balkau B, Charles MA. (1999) Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16: 442-443.
16. Friedewald WT, Levy RI, Fredrickson DS. (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher, DF, Turner RC. (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419
18. McAuley KA, Williams SM, Mann JI, et al. (2001) Diagnosing insulin resistance in the general population. Diabetes Care 24: 460-464.
19. Rhee EJ, Oh KW, Lee WY, et al. (2006) Effects of two common polymorphisms of peroxisome proliferator-activated receptor-γ gene on metabolic syndrome. Arch Med Res 37: 86-94.
20. Purcell S, Cherny SS, Sham PC. (2003) Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19: 149-150.
21. Frederiksen L, Brodbaek K, Fenger M, et al. (2002) Comment: studies of thePro12Ala polymorphism of the PPAR-γ gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab 87: 3989-3992.
22. Gonzalez Sanchez JL, Serrano Rios M, Fernandez PC, Laakso M, Martinez Larrad MT. (2002) Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. Eur J Endocrinol147: 495-501.
23. Li, S, Chen W, Srinivasan SR, Boerwinkle E, Berenson GS. (2003) The peroxisome proliferator-activated receptor-γ2 gene polymorphism (Pro12Ala) beneficially influences insulin resistance and its tracking from childhood to adulthood: the Bogalusa Heart Study. Diabetes 52: 1265-1269.
24. Poulsen P, Andersen G, Fenger M, et al. (2003) Impact of two common polymorphisms in the PPARγ gene on glucose tolerance and plasma insulin profiles in monozygotic and dizygotic twins: thrifty genotype, thrifty phenotype, or both? Diabetes 52: 194-198.
25. Buzzetti R, Petrone A, Ribaudo MC, et al. (2004) The common PPAR-γ2 Pro12Ala variant is associated with greater insulin sensitivity. Eur J Hum Genet 12: 1050-1054.
26. Ghoussaini M, Meyre D, Lobbens S, et al. (2005) Implication of the Pro12Ala polymorphism of the PPAR-γ2 gene in type 2 diabetes and obesity in the French population. BMC Med Genet 6: 11.
27. Pinterova D, Cerna M, Kolostova K, et al. (2004) The frequency of alleles of the Pro12Ala polymorphism in PPAR?2 is different between healthy controls and patients with type 2 diabetes. Folia Biol (Praha) 50: 153-156.
28. Malecki MT, Frey J, Klupa T, et al. (2003) The Pro12Ala polymorphism of PPARγ2 gene and susceptibility to type 2 diabetes mellitus in a Polish population. Diabetes Res Clin Pract 62: 105-111.
29. Hara K, Okada T, Tobe K, et al. (2000) The Pro12Ala polymorphism in PPAR γ2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 271: 212-216.
30. Chuang LM., Hsiung, CA, Chen YD, et al. (2001) Siblingbased association study of the PPARγ2 Pro12Ala polymorphism and metabolic variables in Chinese and Japanese hypertension families: a SAPPHIRe study. Stanford Asian-Pacific Program in Hypertension and Insulin Resistance. J Mol Med 79: 656-664.
31. Moon MK, Cho YM, Jung HS, et al. (2005) Genetic polymorphisms in peroxisome proliferator-activated receptor gamma are associated with Type 2 diabetes mellitus and obesity in the Korean population. Diabet Med 22: 1161-1166.
32. Levy JC, Matthews DR, Hermans MP. (1998) Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21: 2191-2192.
33. Tonjes A, Scholz M, Loeffler M, Stumvoll M. (2006) Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with Pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care 29: 2489-2497.
34. Kubota N, Terauchi Y, Miki H, et al. (1999) PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4: 597-609.
35. Yamauchi T, Kamon J, Waki H, et al. (2001) The mechanisms by which both heterozygous peroxisome proliferatoractivated receptor γ (PPARγ) deficiency and PPARγ agonist improve insulin resistance. J Biol Chem 276: 41245-41254.
36. Miles PD, Barak Y, He W, Evans RM, Olefsky JM. (2000) Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency. J Clin Invest 105: 287-292.
37. Sharma AM, Staels B. (2007) Peroxisome proliferator-activated receptor γ and adipose tissue-understanding obesityrelated changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 92: 386-395.